Decreasing the ability of HCT116 cells to escape from therapy induced senescence by increasing the duration of doxorubicin treatment
Contacts: Maria Anatolievna Zamkova zamkovam@gmail.com Introduction. Due to the toxicity of high doses of chemotherapy, low concentrations used in cancer treatment leads to the development of senescence phenotype in tumor cells, characterized by a block in the cell cycle progression and the absence...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2024-04-01
|
| Series: | Успехи молекулярной онкологии |
| Subjects: | |
| Online Access: | https://umo.abvpress.ru/jour/article/view/651 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839573429414526976 |
|---|---|
| author | N. A. Persiyantseva S. Yu. Vikhrova M. S. Korotkova D. B. Kazansky V. V. Tatarsky M. A. Zamkova |
| author_facet | N. A. Persiyantseva S. Yu. Vikhrova M. S. Korotkova D. B. Kazansky V. V. Tatarsky M. A. Zamkova |
| author_sort | N. A. Persiyantseva |
| collection | DOAJ |
| description | Contacts: Maria Anatolievna Zamkova zamkovam@gmail.com Introduction. Due to the toxicity of high doses of chemotherapy, low concentrations used in cancer treatment leads to the development of senescence phenotype in tumor cells, characterized by a block in the cell cycle progression and the absence of division; changes in the transcriptional and metabolic profile of cells. A negative consequence of this stage is acquisition of individual cells the ability to escape from senescence and return to re-proliferation.Aim. To estimate the effect of the duration of drug treatment of HCT116 tumor cells on their ability to escape from therapy induced senescence.Materials and methods. The senescence phenotype was confirmed by the analysis of β-galactosidase activity; cell cycle analysis; estimation of protein levels by western blotting. Colonies were stained with crystal violet dye.Results. In our study, we showed that the duration of HCT116 cells incubation with low-dose doxorubicin affects their ability to return to re-proliferation – increasing the treatment time using same drug dose reduces the process of colony formation. The duration of doxorubicin treatment does not affect the formation of the senescence phenotype, which was confirmed by analyzing different markers of this stage (changes in β-galactosidase activity, cell cycle analysis, assessment of p21 and γH2AX protein levels). However, there is a delay in the development of cellular response to DNA damage caused by doxorubicin in cells exposed to prolong treatment protocol (increase in β-galactosidase activity, formation of polyploid cells).Conclusion. The duration of doxorubicin treatment of HCT116 cancer cells affects long-term consequences, reducing the ability of senescent cells to escape this stage when the incubation time with the drug is extended. |
| format | Article |
| id | doaj-art-bcd02d08ca6f4621b51be5b5cc3490d0 |
| institution | Matheson Library |
| issn | 2313-805X 2413-3787 |
| language | Russian |
| publishDate | 2024-04-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Успехи молекулярной онкологии |
| spelling | doaj-art-bcd02d08ca6f4621b51be5b5cc3490d02025-08-04T14:04:37ZrusABV-pressУспехи молекулярной онкологии2313-805X2413-37872024-04-01111909810.17650/2313-805X-2024-11-1-90-98320Decreasing the ability of HCT116 cells to escape from therapy induced senescence by increasing the duration of doxorubicin treatmentN. A. Persiyantseva0S. Yu. Vikhrova1M. S. Korotkova2D. B. Kazansky3V. V. Tatarsky4M. A. Zamkova5N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; Sechenov First Moscow State Medical UniversityN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; Sechenov First Moscow State Medical UniversityN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaInstitute of Gene Biology Russian Academy of SciencesN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; Institute of Gene Biology Russian Academy of SciencesContacts: Maria Anatolievna Zamkova zamkovam@gmail.com Introduction. Due to the toxicity of high doses of chemotherapy, low concentrations used in cancer treatment leads to the development of senescence phenotype in tumor cells, characterized by a block in the cell cycle progression and the absence of division; changes in the transcriptional and metabolic profile of cells. A negative consequence of this stage is acquisition of individual cells the ability to escape from senescence and return to re-proliferation.Aim. To estimate the effect of the duration of drug treatment of HCT116 tumor cells on their ability to escape from therapy induced senescence.Materials and methods. The senescence phenotype was confirmed by the analysis of β-galactosidase activity; cell cycle analysis; estimation of protein levels by western blotting. Colonies were stained with crystal violet dye.Results. In our study, we showed that the duration of HCT116 cells incubation with low-dose doxorubicin affects their ability to return to re-proliferation – increasing the treatment time using same drug dose reduces the process of colony formation. The duration of doxorubicin treatment does not affect the formation of the senescence phenotype, which was confirmed by analyzing different markers of this stage (changes in β-galactosidase activity, cell cycle analysis, assessment of p21 and γH2AX protein levels). However, there is a delay in the development of cellular response to DNA damage caused by doxorubicin in cells exposed to prolong treatment protocol (increase in β-galactosidase activity, formation of polyploid cells).Conclusion. The duration of doxorubicin treatment of HCT116 cancer cells affects long-term consequences, reducing the ability of senescent cells to escape this stage when the incubation time with the drug is extended.https://umo.abvpress.ru/jour/article/view/651hct116doxorubicinsenescencecolony formation |
| spellingShingle | N. A. Persiyantseva S. Yu. Vikhrova M. S. Korotkova D. B. Kazansky V. V. Tatarsky M. A. Zamkova Decreasing the ability of HCT116 cells to escape from therapy induced senescence by increasing the duration of doxorubicin treatment Успехи молекулярной онкологии hct116 doxorubicin senescence colony formation |
| title | Decreasing the ability of HCT116 cells to escape from therapy induced senescence by increasing the duration of doxorubicin treatment |
| title_full | Decreasing the ability of HCT116 cells to escape from therapy induced senescence by increasing the duration of doxorubicin treatment |
| title_fullStr | Decreasing the ability of HCT116 cells to escape from therapy induced senescence by increasing the duration of doxorubicin treatment |
| title_full_unstemmed | Decreasing the ability of HCT116 cells to escape from therapy induced senescence by increasing the duration of doxorubicin treatment |
| title_short | Decreasing the ability of HCT116 cells to escape from therapy induced senescence by increasing the duration of doxorubicin treatment |
| title_sort | decreasing the ability of hct116 cells to escape from therapy induced senescence by increasing the duration of doxorubicin treatment |
| topic | hct116 doxorubicin senescence colony formation |
| url | https://umo.abvpress.ru/jour/article/view/651 |
| work_keys_str_mv | AT napersiyantseva decreasingtheabilityofhct116cellstoescapefromtherapyinducedsenescencebyincreasingthedurationofdoxorubicintreatment AT syuvikhrova decreasingtheabilityofhct116cellstoescapefromtherapyinducedsenescencebyincreasingthedurationofdoxorubicintreatment AT mskorotkova decreasingtheabilityofhct116cellstoescapefromtherapyinducedsenescencebyincreasingthedurationofdoxorubicintreatment AT dbkazansky decreasingtheabilityofhct116cellstoescapefromtherapyinducedsenescencebyincreasingthedurationofdoxorubicintreatment AT vvtatarsky decreasingtheabilityofhct116cellstoescapefromtherapyinducedsenescencebyincreasingthedurationofdoxorubicintreatment AT mazamkova decreasingtheabilityofhct116cellstoescapefromtherapyinducedsenescencebyincreasingthedurationofdoxorubicintreatment |